is semaglutide going off the market FDA Warns on Certain Forms of Compounded Novo cuts GLP-1 prices 70%,

However, factors like timing and test usage can influence outcomes

Some research suggests discontinuation rates for GLP-1s may be significantly higher in the real world, particularly in people with obesity

This form of Semaglutide is NOT produced nor condoned by Novo Nordisk, who are the only license holder for manufacturing & distributing Semaglutide

A Decision Framework Lean toward Contrave if: Eating is primarily driven by cravings, reward-seeking, or emotional triggers You have depression that might benefit from bupropion You strongly prefer oral medication You cannot take GLP-1 medications Insurance covers Contrave but not semaglutide Weight loss goals are more modest (5-10%) Lean toward semaglutide if: You want maximum weight loss (15%+) You have cardiovascular disease or high risk You have diabetes or prediabetes Your eating is driven by persistent hunger and difficulty feeling full You prefer weekly over daily medication You can afford it or have coverage Either might work if: You have mixed eating patterns No clear medical factor driving choice Both are accessible and affordable Moderate weight loss would meet your goals Discuss With Your Provider Bring these considerations to your healthcare provider: Your specific eating patterns and challenges Your complete medical history and current medications Your weight loss goals Your insurance coverage and budget Your preferences about administration Your provider can help weigh these factors against your specific health profile